Paggiarino Dario A.
Insider CIK 1574261 · LPTN Sr VP & Chief Dev. Officer · PSDV Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-03-30 | 2024-04-02 | 30,570 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-03-30 | 2024-04-02 | 5,834 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-03-30 | 2024-04-02 | 14,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-03-30 | 2024-04-02 | 2,957 | $20.67 | $61.1K | 74,176 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-03-30 | 2024-04-02 | 15,493 | $20.67 | $320.2K | 77,133 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-03-30 | 2024-04-02 | 7,096 | $20.67 | $146.7K | 67,080 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-03-30 | 2024-04-02 | 5,834 | — | $0 | 48,056 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-03-30 | 2024-04-02 | 30,570 | — | $0 | 78,626 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-03-30 | 2024-04-02 | 14,000 | — | $0 | 92,626 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 4,967 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 5,833 | — | $0 | 5,834 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 4,967 | — | $0 | 41,472 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 5,833 | — | $0 | 47,305 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 2,565 | $28.80 | $73.9K | 42,222 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 2,518 | $28.80 | $72.5K | 44,787 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-26 | 2024-01-30 | 15,609 | — | $0 | 1,026 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-26 | 2024-01-30 | 33,665 | — | $0 | 17,588 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-26 | 2024-01-30 | 51 | — | $0 | 51,253 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-26 | 2024-01-30 | 33,665 | $25.77 | $867.5K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-26 | 2024-01-30 | 15,609 | $25.41 | $396.6K | 70,170 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-26 | 2024-01-30 | 51 | $25.41 | $1.3K | 85,779 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-26 | 2024-01-30 | 33,665 | $13.13 | $442.0K | 85,830 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-26 | 2024-01-30 | 51 | $13.13 | $670 | 52,165 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-26 | 2024-01-30 | 15,609 | $12.90 | $201.4K | 52,114 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-25 | 2024-01-29 | 300 | — | $0 | 16,635 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-25 | 2024-01-29 | 300 | — | $0 | 51,304 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-25 | 2024-01-29 | 300 | $12.90 | $3.9K | 37,105 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-25 | 2024-01-29 | 300 | $25.00 | $7.5K | 36,805 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-25 | 2024-01-29 | 300 | $25.00 | $7.5K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-25 | 2024-01-29 | 300 | $13.13 | $3.9K | 36,805 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-24 | 2024-01-25 | 5,600 | — | $0 | 51,604 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-24 | 2024-01-25 | 5,651 | — | $0 | 16,935 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-24 | 2024-01-25 | 5,600 | $25.01 | $140.1K | 42,156 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-24 | 2024-01-25 | 5,651 | $12.90 | $72.9K | 42,156 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-24 | 2024-01-25 | 5,600 | $13.13 | $73.5K | 47,756 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-24 | 2024-01-25 | 5,651 | $25.02 | $141.4K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-23 | 2024-01-25 | 3,096 | — | $0 | 57,204 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-23 | 2024-01-25 | 2,039 | — | $0 | 22,586 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-23 | 2024-01-25 | 3,096 | $13.13 | $40.7K | 39,601 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-23 | 2024-01-25 | 3,096 | $25.00 | $77.4K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-23 | 2024-01-25 | 2,039 | $25.00 | $51.0K | 39,601 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-23 | 2024-01-25 | 2,039 | $12.90 | $26.3K | 41,640 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-08 | 2024-01-10 | 22,913 | — | $0 | 68,742 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-08 | 2024-01-10 | 22,913 | $3.26 | $74.7K | 59,418 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-08 | 2024-01-10 | 22,913 | $21.13 | $484.2K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-06 | 2024-01-09 | 15,285 | — | $0 | 30,570 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-01-06 | 2024-01-09 | 4,487 | $20.40 | $91.5K | 36,505 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-06 | 2024-01-09 | 15,285 | — | $0 | 40,992 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 42,000 | — | $0 | 42,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 21,000 | — | $0 | 21,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-12-13 | 2023-12-15 | 1,458 | — | $0 | 37,917 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2023-12-13 | 2023-12-15 | 1,458 | $20.00 | $29.2K | 25,707 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-12-13 | 2023-12-15 | 1,458 | $10.13 | $14.8K | 27,165 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-12-04 | 2023-12-06 | 30,625 | — | $0 | 39,375 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2023-12-04 | 2023-12-06 | 30,625 | $22.00 | $673.8K | 25,707 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-12-04 | 2023-12-06 | 30,625 | $10.13 | $310.2K | 56,332 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-06-20 | 2023-06-22 | 45,855 | — | $0 | 45,855 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 5,833 | — | $0 | 11,667 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 4,967 | — | $0 | 4,967 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2023-02-09 | 2023-02-13 | 1,722 | $4.17 | $7.2K | 25,707 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2023-02-09 | 2023-02-13 | 2,022 | $4.17 | $8.4K | 27,429 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 5,833 | — | $0 | 29,451 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 4,967 | — | $0 | 23,618 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-01-06 | 2023-01-10 | 91,655 | — | $0 | 91,655 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-28 | 2022-03-02 | 4,105 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2022-02-28 | 2022-03-02 | 1,294 | $9.95 | $12.9K | 18,651 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-28 | 2022-03-02 | 4,105 | — | $0 | 19,945 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 17,500 | — | $0 | 17,500 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 70,000 | — | $0 | 70,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-09 | 2022-02-11 | 4,966 | — | $0 | 9,934 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-09 | 2022-02-11 | 4,966 | — | $0 | 17,561 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2022-02-09 | 2022-02-11 | 1,721 | $10.13 | $17.4K | 15,840 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 60,300 | — | $0 | 60,300 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 14,900 | — | $0 | 14,900 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-06-14 | 2021-06-15 | 1,420 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-06-14 | 2021-06-15 | 1,420 | — | $0 | 13,012 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2021-06-14 | 2021-06-15 | 417 | $9.72 | $4.1K | 12,595 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-02-28 | 2021-03-02 | 4,105 | — | $0 | 4,105 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2021-02-28 | 2021-03-02 | 1,423 | $10.81 | $15.4K | 11,592 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-02-28 | 2021-03-02 | 4,105 | — | $0 | 13,015 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-30 | 2020-07-02 | 41,050 | — | $0 | 82,100 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2020-06-30 | 2020-07-02 | 12,049 | $0.76 | $9.2K | 89,144 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-30 | 2020-07-02 | 41,050 | — | $0 | 101,193 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-27 | 2020-06-30 | 10,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-27 | 2020-06-30 | 10,000 | — | $0 | 63,079 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2020-06-27 | 2020-06-30 | 2,936 | $0.79 | $2.3K | 60,143 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-14 | 2020-06-16 | 14,200 | — | $0 | 14,200 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-14 | 2020-06-16 | 14,200 | — | $0 | 57,247 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2020-06-14 | 2020-06-16 | 4,168 | $0.83 | $3.5K | 53,079 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 123,150 | — | $0 | 123,150 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 246,250 | — | $0 | 246,250 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2019-10-12 | 2019-10-15 | 2,450 | $2.11 | $5.2K | 43,047 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2019-06-27 | 2019-06-28 | 10,000 | — | $0 | 10,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2019-06-27 | 2019-06-28 | 10,000 | — | $0 | 48,437 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2019-06-27 | 2019-06-28 | 2,940 | $1.65 | $4.9K | 45,497 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2019-06-25 | 2019-06-27 | 370,000 | — | $0 | 370,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2019-06-14 | 2019-06-17 | 14,200 | — | $0 | 28,400 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2019-06-14 | 2019-06-17 | 4,175 | $1.53 | $6.4K | 38,437 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2019-06-14 | 2019-06-17 | 14,200 | — | $0 | 42,612 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2019-03-19 | 2019-03-21 | 1,188 | $2.47 | $2.9K | 28,412 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award | 2018-10-12 | 2018-10-16 | 16,667 | — | $0 | 32,055 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2018-10-12 | 2018-10-16 | 2,455 | $3.23 | $7.9K | 29,600 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2018-06-27 | 2018-06-29 | 10,000 | — | $0 | 20,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2018-06-27 | 2018-06-29 | 10,000 | — | $0 | 18,333 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2018-06-27 | 2018-06-29 | 2,945 | $1.86 | $5.5K | 15,388 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2018-06-14 | 2018-06-18 | 42,600 | — | $0 | 42,600 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2018-06-14 | 2018-06-18 | 170,500 | — | $0 | 170,500 | SEC↗ |
| PSDV pSivida Corp. | A Award | 2018-03-19 | 2018-03-21 | 8,333 | — | $0 | 8,333 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2017-06-27 | 2017-06-29 | 60,000 | — | $0 | 60,000 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2017-06-27 | 2017-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2016-08-01 | 2016-08-03 | 230,000 | — | $0 | 230,000 | SEC↗ |
| LPTN LPATH, INC | A Award deriv | 2016-02-16 | 2016-02-18 | 100,000 | — | $0 | 100,000 | SEC↗ |
| LPTN LPATH, INC | A Award deriv | 2015-06-16 | 2015-06-18 | 150,000 | — | $0 | 150,000 | SEC↗ |
| LPTN LPATH, INC | A Award deriv | 2015-02-09 | 2015-02-11 | 50,000 | — | $0 | 50,000 | SEC↗ |
| LPTN LPATH, INC | A Award deriv | 2014-02-10 | 2014-02-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| LPTN LPATH, INC | A Award deriv | 2013-06-19 | 2013-06-27 | 100,000 | — | $0 | 100,000 | SEC↗ |